Patents by Inventor John C. Timmer

John C. Timmer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD33 TARGETED IMMUNOTHERAPIES
    Publication number: 20260132184
    Abstract: The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
    Type: Application
    Filed: January 12, 2026
    Publication date: May 14, 2026
    Applicants: Regeneron Pharmaceuticals, Inc., Inhibrx Biosciences, Inc.
    Inventors: Jordan Jarjour, Mark Pogson, Wai-Hang Leung, Kyle Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • 5T4 single domain antibodies and therapeutic compositions thereof
    Patent number: 12590169
    Abstract: Provided herein are binding polypeptides that specifically bind 5T4. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind 5T4. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided 5T4 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: March 31, 2026
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, Michael D. Kaplan, Katelyn M. Willis, Rajay A. Pandit, Angelica N. Sanabria, Sydney A. Barnes, Margaret E. Haerr, Brendan P. Eckelman, Rutger H. Jackson
  • CLL-1 TARGETED IMMUNOTHERAPIES
    Publication number: 20260055192
    Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory discase, and immunodeficiency, or condition associated therewith.
    Type: Application
    Filed: August 27, 2025
    Publication date: February 26, 2026
    Applicants: Regeneron Pharmaceuticals, Inc., Inhibrx Biosciences, Inc.
    Inventors: Jordan Jarjour, Mark Pogson, Wai-Hang Leung, Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan Eckelman
  • CD33 targeted immunotherapies
    Patent number: 12552855
    Abstract: The present disclosure provides improved CD33 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: February 17, 2026
    Assignees: Regeneron Pharmaceuticals, Inc., Inhibrx Biosciences, Inc.
    Inventors: Jordan Jarjour, Mark Pogson, Wai-Hang Leung, Kyle Jones, William Crago, Angelica Sanabria, Andrew Hollands, Jacob Gano, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • CD28 single domain antibodies and multivalent and multispecific constructs thereof
    Patent number: 12522661
    Abstract: Provided herein are binding polypeptides that specifically bind CD28. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs that bind at least CD28. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors thereof, and methods of use and uses of the provided CD28 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: January 13, 2026
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, Rutger H. Jackson, Katelyn M. Willis, William S. Crago, Michael D. Kaplan, Brendan P. Eckelman
  • OX40-Binding Polypeptides and Uses Thereof
    Publication number: 20260008860
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: May 15, 2025
    Publication date: January 8, 2026
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan R. Becklund, Brendan P. Eckelman
  • MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES
    Publication number: 20250361319
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Application
    Filed: May 12, 2025
    Publication date: November 27, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, John C. TIMMER
  • FcRn-Binding Polypeptides and Uses Thereof
    Publication number: 20250353911
    Abstract: Provided herein are VHH-containing polypeptides that bind FcRn. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: June 9, 2023
    Publication date: November 20, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman, Florian Sulzmaier
  • CD8-Binding Polypeptides and Uses Thereof
    Publication number: 20250320295
    Abstract: Provided herein are VHH-containing polypeptides that bind CD8. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: July 19, 2022
    Publication date: October 16, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, William Crago, Florian Sulzmaier, Lucas Rascon, Brendan P. Eckelman
  • DLL3 SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC COMPOSITIONS THEREOF
    Publication number: 20250313623
    Abstract: Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Application
    Filed: June 18, 2025
    Publication date: October 9, 2025
    Inventors: Brendan P. ECKELMAN, Michael D. KAPLAN, Katelyn M. WILLIS, Rajay A. PANDIT, Angelica N. SANABRIA, Sydney A. BARNES, Margaret E. HAERR, John C. TIMMER
  • CLL-1 targeted immunotherapies
    Patent number: 12421315
    Abstract: The present disclosure provides improved CLL-1 targeting polypeptides and compositions for adoptive T cell therapies for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: September 23, 2025
    Assignees: Regeneron Pharmaceuticals, Inc., Inhibrx Biosciences, Inc.
    Inventors: Jordan Jarjour, Mark Pogson, Wai-Hang Leung, Lucas Rascon, Angelica Sanabria, John C. Timmer, Brendan P. Eckelman
  • Albumin-Binding Polypeptides and Uses Thereof
    Publication number: 20250277018
    Abstract: Provided herein are VHH-containing polypeptides that bind albumin. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: May 4, 2023
    Publication date: September 4, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Andrew Hollands, Milton Ma, John C. Timmer, Brendan P. Eckelman
  • USES OF PDL1-BINDING PROTEINS
    Publication number: 20250250349
    Abstract: This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.
    Type: Application
    Filed: November 22, 2024
    Publication date: August 7, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, John C. Timmer, Chelsie Macedo, Kyle S. Jones, Abrahim Hussain, Amir S. Razai, Bryan R. Becklund, Rajay A. Pandit, Mike Kaplan, Lucas Rascon, Quinn Deveraux
  • DLL3 single domain antibodies and therapeutic compositions thereof
    Patent number: 12365728
    Abstract: Provided herein are binding polypeptides that specifically bind DLL3. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific contracts and chimeric antigen receptors, that bind DLL3. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided DLL3 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: October 9, 2019
    Date of Patent: July 22, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, Rajay A. Pandit, Angelica N. Sanabria, Sydney A. Barnes, Margaret E. Haerr, John C. Timmer
  • NON-IMMUNOGENIC SINGLE DOMAIN ANTIBODIES
    Publication number: 20250223338
    Abstract: The invention provides modifications within human or humanized single domain antibody fragments (sdAbs) that prevent recognition by pre-existing antibodies, to isolated polypeptides that include these modifications, and to methods and uses thereof.
    Type: Application
    Filed: August 16, 2024
    Publication date: July 10, 2025
    Inventors: Brendan P. ECKELMAN, John C. TIMMER, Quinn DEVERAUX
  • OX40-binding polypeptides and uses thereof
    Patent number: 12331126
    Abstract: Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.
    Type: Grant
    Filed: May 8, 2024
    Date of Patent: June 17, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, William Crago, Kyle Jones, Katelyn Willis, Florian Sulzmaier, Bryan Becklund, Brendan P. Eckelman
  • Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses
    Patent number: 12331132
    Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
    Type: Grant
    Filed: June 6, 2023
    Date of Patent: June 17, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, John C. Timmer
  • PD-1 single domain antibodies and therapeutic compositions thereof
    Patent number: 12297271
    Abstract: Provided herein are binding polypeptides that specifically bind PD-1. More specifically, provided herein are fusion proteins, including multivalent and/or multispecific constructs and chimeric antigen receptors, that bind PD-1. Also provided are pharmaceutical compositions containing the polypeptides, nucleic acid molecules encoding the polypeptides and vectors and cells thereof, and methods of use and uses of the provided PD-1 binding polypeptides for treating diseases and conditions, such as cancer.
    Type: Grant
    Filed: February 28, 2024
    Date of Patent: May 13, 2025
    Assignee: Inhibrx Biosciences, Inc.
    Inventors: Rajay A. Pandit, John C. Timmer, Angelica N. Sanabria, Florian Sulzmaier, Brendan P. Eckelman
  • NKp46-Binding Polypeptides and Uses Thereof
    Publication number: 20250136681
    Abstract: Provided herein are VHH-containing polypeptides that bind NKp46. Uses of the VHH-containing polypeptides are also provided.
    Type: Application
    Filed: August 29, 2022
    Publication date: May 1, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: John C. Timmer, Brendan P. Eckelman, Rajay A. Pandit, William Crago, Florian Sulzmaier, Heather Kinkead, Nadja Kern
  • Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof
    Publication number: 20250109203
    Abstract: Provided herein are polypeptides comprising at least one VHH domain that binds ?? TCR and a modified IL-2. Uses of the polypeptides are also provided.
    Type: Application
    Filed: January 4, 2023
    Publication date: April 3, 2025
    Applicant: Inhibrx Biosciences, Inc.
    Inventors: Bryan R. Becklund, Kyle S. Jones, Kaitlyn N. Robinson, Andrew M. Eckles, John C. Timmer, Brendan P. Eckelman